Efficacy of Lusutrombopag for Thrombocytopenia in Patients with Chronic Liver Disease Scheduled to Undergo Invasive Procedures

Objective Lusutrombopag is a thrombopoietin receptor agonist that improves thrombocytopenia in patients with chronic liver disease scheduled to undergo invasive procedures. However, information on the efficacy of repeated lusutrombopag treatment and factors associated with the treatment is scarce. We analyzed the efficacy of repeated lusutrombopag treatment and the factors associated with a response to lusutrombopag. Methods Thirty-nine patients with chronic liver disease who received lusutrombopag treatment before undergoing invasive procedures were enrolled in this retrospective study. Of the 39 patients, 10 received lusutrombopag treatment multiple times for a total of 53 regimens of lusutrombopag treatment. Changes in platelet counts, the effects of repeated lusutrombopag treatment, and factors associated with response to lusutrombopag were analyzed. Results The median platelet count increased significantly from 4.5×104/μL before lusutrombopag treatment to 7.2×104/μL before the invasive procedure (p<0.01), and patients undergoing 49 of the 53 (92%) treatment regimens succeeded in undergoing invasive procedures without needing platelet transfusions. In patients who received lusutrombopag treatment repeatedly, the median platelet count significantly increased following the second administration of lusutrombopag, and the effects of lusutrombopag were similar between the first and second administration. A multivariate analysis identified the absence of diabetes mellitus (odds ratio, 5.56 for presence; p=0.04) as a significant and independent predictor of a response to lusutrombopag. Conclusion Lusutrombopag treatment significantly increased platelet counts in patients with chronic liver disease, making it possible to receive invasive procedures. The treatment produced identical effects when it was repeated. The efficacy of lusutrombopag might be decreased in patients with diabetes mellitus.

[1]  T. Itoi,et al.  Thrombopoietin receptor agonist is more effective than platelet transfusion for chronic liver disease with thrombocytopenia, shown by propensity score matching , 2020, Hepatology research : the official journal of the Japan Society of Hepatology.

[2]  Y. Hiasa,et al.  Role of severe thrombocytopenia in preventing platelet count recovery in thrombocytopenic patients with chronic liver disease , 2020, Journal of gastroenterology and hepatology.

[3]  H. Yoshiji,et al.  Effectiveness of Lusutrombopag in Patients with Mild to Moderate Thrombocytopenia , 2019, Digestive Diseases.

[4]  N. Afdhal,et al.  Safety and effectiveness of lusutrombopag in Japanese chronic liver disease patients with thrombocytopenia undergoing invasive procedures: Interim results of a postmarketing surveillance , 2019, Hepatology research : the official journal of the Japan Society of Hepatology.

[5]  M. Kudo,et al.  Lusutrombopag Reduces Need for Platelet Transfusion in Patients With Thrombocytopenia Undergoing Invasive Procedures , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[6]  K. Simon,et al.  Lusutrombopag for the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing Invasive Procedures (L‐PLUS 2) , 2019, Hepatology.

[7]  N. Enomoto,et al.  Real-life experience of lusutrombopag for cirrhotic patients with low platelet counts being prepared for invasive procedures , 2019, PloS one.

[8]  T. Ishikawa,et al.  Efficacy and safety of repeated use of lusutrombopag prior to radiofrequency ablation in patients with recurrent hepatocellular carcinoma and thrombocytopenia , 2019, Hepatology research : the official journal of the Japan Society of Hepatology.

[9]  K. Iwakiri,et al.  Relationship between response to lusutrombopag and splenic volume , 2018, World journal of gastroenterology.

[10]  M. Kudo,et al.  A randomized controlled trial of lusutrombopag in Japanese patients with chronic liver disease undergoing radiofrequency ablation , 2018, Journal of Gastroenterology.

[11]  N. Ishimura,et al.  Efficacy of Repeated Lusutrombopag Administration for Thrombocytopenia in a Patient Scheduled for Invasive Hepatocellular Carcinoma Treatment , 2017, Internal medicine.

[12]  W. Bergmeier,et al.  Sugar makes neutrophils RAGE: linking diabetes-associated hyperglycemia to thrombocytosis and platelet reactivity. , 2017, The Journal of clinical investigation.

[13]  M. Febbraio,et al.  Neutrophil-derived S100 calcium-binding proteins A8/A9 promote reticulated thrombocytosis and atherogenesis in diabetes , 2017, The Journal of clinical investigation.

[14]  R. D. de Knegt,et al.  Management of Thrombocytopenia in Chronic Liver Disease: Focus on Pharmacotherapeutic Strategies , 2015, Drugs.

[15]  T. Ishikawa,et al.  Telaprevir-based triple therapy following partial splenic arterial embolization for chronic hepatitis C with thrombocytopenia can reduce carcinogenesis and improve hepatic function reserve , 2015, Experimental and therapeutic medicine.

[16]  Esther S. Kim,et al.  Lusutrombopag: First Global Approval , 2015, Drugs.

[17]  S. T. Mees,et al.  Laparoscopic splenectomy for medically refractory immune thrombocytopenia (ITP): a retrospective cohort study on longtime response predicting factors based on consensus criteria. , 2014, International journal of surgery.

[18]  Y. Maehara,et al.  Management of thrombocytopenia due to liver cirrhosis: a review. , 2014, World journal of gastroenterology.

[19]  Y. Kanda,et al.  Investigation of the freely available easy-to-use software ‘EZR' for medical statistics , 2012, Bone Marrow Transplantation.

[20]  Kohjiro Ueki,et al.  Report of the Committee on the Classification and Diagnostic Criteria of Diabetes Mellitus , 2010, Journal of diabetes investigation.

[21]  M. Manns,et al.  Thrombocytopenia associated with chronic liver disease. , 2008, Journal of hepatology.

[22]  E. Giannini.  Review article: thrombocytopenia in chronic liver disease and pharmacologic treatment options , 2006, Alimentary pharmacology & therapeutics.

[23]  J. Prieto,et al.  The Role of Thrombopoietin in the Thrombocytopenia of Patients with Liver Cirrhosis , 2005, The American Journal of Gastroenterology.

[24]  R. Testa,et al.  Relationship between thrombopoietin serum levels and liver function in patients with chronic liver disease related to hepatitis C virus infection , 2003, American Journal of Gastroenterology.

[25]  P. Perrotta,et al.  Non-infectious complications of transfusion therapy. , 2001, Blood reviews.

[26]  J. McCullough.  Current issues with platelet transfusion in patients with cancer. , 2000, Seminars in hematology.

[27]  F. Gries,et al.  Large Platelets Circulate in an Activated State in Diabetes Mellitus , 1991, Seminars in thrombosis and hemostasis.

[28]  Y. Morikawa,et al.  Ultrasonographic determination of the splenic size and its clinical usefulness in various liver diseases. , 1975, Radiology.